Marrow Daily Core
21.5K subscribers
595 photos
32 videos
313 files
260 links
Cerebellum discount code - ๐‘ด๐‘จ๐‘ฎ๐‘ฐ๐‘ช๐‘ฉ๐‘ป๐‘น
๐Ÿฉท Prepladder discount code - PLAN
Whatโ€™s app channel tinyurl.com/examfmge
Download Telegram
#URGENT

NBEMS has given final opportunity for candidates who need to change the rejected images in application form.

Attaching a list of candidates whose images are rejected.

https://natboard.edu.in/viewUpload?xyz=ZWVrRHI0SkZ6WFVkZDhXWmdySkpzdz09

https://whatsapp.com/channel/0029VanTshI0LKZAZreeWS46
โค2
*Important: NEET PG 2026 CITY ALLOTMENT*

The message everyone is getting is wrong. Don't worry.

Login & see the allotted city, that's the correct one.

People are getting random messages. Ignore.

Login here https://cdn3.digialm.com/EForms/configuredHtml/1815/94357/login.html
๐Ÿ‘2โค1
๐Ÿ‡ฎ๐Ÿ‡ณ๐—–๐—ฒ๐—ฟ๐—ฒ๐—ฏ๐—ฒ๐—น๐—น๐˜‚๐—บ 10% ๐—ข๐—ณ๐—ณ๐—ฒ๐—ฟ๐Ÿ‡ฎ๐Ÿ‡ณ

โœ…๐—–๐—ผ๐˜‚๐—ฝ๐—ผ๐—ป ๐—–๐—ผ๐—ฑ๐—ฒ - MAGICBTR

โžก๏ธ๐— ๐—ถ๐˜€๐˜€๐—ถ๐—ผ๐—ป 200+ ๐—™๐— ๐—š๐—˜
โ–ช๏ธ๐—ก๐—ฒ๐˜„ ๐—•๐—ฎ๐˜๐—ฐ๐—ต ๐—ฆ๐˜๐—ฎ๐—ฟ๐˜๐—ถ๐—ป๐—ด ๐—™๐—ฟ๐—ผ๐—บ 21๐˜€๐˜ ๐—”๐˜‚๐—ด, 2026

โ–ซ๏ธ6 ๐— ๐—ผ๐—ป๐˜๐—ต๐˜€ ๐—ฃ๐—น๐—ฎ๐—ป ๐—ฃ๐—ฟ๐—ถ๐—ฐ๐—ฒ - 22,500/-
โ–ซ๏ธ12 ๐— ๐—ผ๐—ป๐˜๐—ต๐˜€ ๐—ฃ๐—น๐—ฎ๐—ป ๐—ฃ๐—ฟ๐—ถ๐—ฐ๐—ฒ - 30,600/-

๐Ÿ”Š๐—ข๐—ณ๐—ณ๐—ฒ๐—ฟ ๐—ถ๐˜€ ๐˜ƒ๐—ฎ๐—น๐—ถ๐—ฑ ๐˜๐—ถ๐—น๐—น 17๐˜๐—ต ๐—”๐˜‚๐—ด๐˜‚๐˜€๐˜

๐Ÿ’ธ๐— ๐—ฎ๐—ธ๐—ฒ ๐—ฝ๐—ฎ๐˜†๐—บ๐—ฒ๐—ป๐˜ ๐˜๐—ต๐—ฟ๐—ผ๐˜‚๐—ด๐—ต ๐˜„๐—ฒ๐—ฏ๐˜€๐—ถ๐˜๐—ฒ
https://dashboard.cerebellumacademy.com/plans

โ˜‘๏ธ๐—จ๐˜€๐—ฒ ๐—–๐—ผ๐˜‚๐—ฝ๐—ผ๐—ป ๐—–๐—ผ๐—ฑ๐—ฒ - MAGICBTR
+917232021140
โค2
๐Ÿ”ฅ ๐—ก๐—˜๐—˜๐—ง ๐—ฃ๐—š ๐Ÿฎ๐Ÿฌ๐Ÿฎ๐Ÿฒ โ€” ๐Ÿญ๐Ÿฑ ๐——๐—”๐—ฌ๐—ฆ ๐—Ÿ๐—˜๐—™๐—ง ๐Ÿ”ฅ
๐ŸŽฏ ๐‘ฏ๐‘ฐ๐‘ฎ๐‘ฏ-๐’€๐‘ฐ๐‘ฌ๐‘ณ๐‘ซ ๐‘น๐‘ฌ๐‘ฝ๐‘ฐ๐‘บ๐‘ฐ๐‘ถ๐‘ต ๐‘บ๐‘ฌ๐‘น๐‘ฐ๐‘ฌ๐‘บ

๐Ÿ“š ๐—ฆ๐—˜๐—ง ๐Ÿญ/๐Ÿณ โ€” ๐Ÿญ๐Ÿฑ ๐— ๐—จ๐—ฆ๐—ง-๐—ฅ๐—˜๐—ฉ๐—œ๐—ฆ๐—˜ ๐—ง๐—ข๐—ฃ๐—œ๐—–๐—ฆ

โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”

๐Ÿซ€ ๐—š๐—˜๐—ก๐—˜๐—ฅ๐—”๐—Ÿ ๐— ๐—˜๐——๐—œ๐—–๐—œ๐—ก๐—˜

โ‘  ๐—˜๐—–๐—š + ๐—”๐—ฟ๐—ฟ๐—ต๐˜†๐˜๐—ต๐—บ๐—ถ๐—ฎ๐˜€
โ†’ ๐‘ฌ๐‘ช๐‘ฎ ๐’Š๐’๐’•๐’†๐’“๐’‘๐’“๐’†๐’•๐’‚๐’•๐’Š๐’๐’ + ๐’„๐’๐’Ž๐’Ž๐’๐’ ๐’•๐’‚๐’„๐’‰๐’š๐’‚๐’“๐’“๐’‰๐’š๐’•๐’‰๐’Ž๐’Š๐’‚๐’” / ๐’ƒ๐’“๐’‚๐’…๐’š๐’‚๐’“๐’“๐’‰๐’š๐’•๐’‰๐’Ž๐’Š๐’‚๐’”

โ‘ก ๐—”๐—–๐—ฆ + ๐— ๐˜†๐—ผ๐—ฐ๐—ฎ๐—ฟ๐—ฑ๐—ถ๐—ฎ๐—น ๐—œ๐—ป๐—ณ๐—ฎ๐—ฟ๐—ฐ๐˜๐—ถ๐—ผ๐—ป
โ†’ ๐‘ฌ๐‘ช๐‘ฎ ๐’„๐’‰๐’‚๐’๐’ˆ๐’†๐’” + ๐’ƒ๐’Š๐’๐’Ž๐’‚๐’“๐’Œ๐’†๐’“๐’” + ๐’Ž๐’‚๐’๐’‚๐’ˆ๐’†๐’Ž๐’†๐’๐’•

โ‘ข ๐—›๐—ฒ๐—ฎ๐—ฟ๐˜ ๐—™๐—ฎ๐—ถ๐—น๐˜‚๐—ฟ๐—ฒ
โ†’ ๐—›๐—™๐—ฟ๐—˜๐—™ / ๐—›๐—™๐—ฝ๐—˜๐—™ + ๐—ฑ๐—ฟ๐˜‚๐—ด๐˜€ + ๐’‚๐’„๐’–๐’•๐’† ๐’Ž๐’‚๐’๐’‚๐’ˆ๐’†๐’Ž๐’†๐’๐’•

โ‘ฃ ๐—ฉ๐—ฎ๐—น๐˜ƒ๐˜‚๐—น๐—ฎ๐—ฟ ๐—›๐—ฒ๐—ฎ๐—ฟ๐˜ ๐——๐—ถ๐˜€๐—ฒ๐—ฎ๐˜€๐—ฒ
โ†’ ๐‘ด๐’–๐’“๐’Ž๐’–๐’“๐’” + ๐’„๐’๐’Š๐’๐’Š๐’„๐’‚๐’ ๐’‡๐’Š๐’๐’…๐’Š๐’๐’ˆ๐’” + ๐’Ž๐’‚๐’๐’‚๐’ˆ๐’†๐’Ž๐’†๐’๐’•

โ‘ค ๐—ฆ๐˜๐—ฟ๐—ผ๐—ธ๐—ฒ + ๐—Ÿ๐—ผ๐—ฐ๐—ฎ๐—น๐—ถ๐˜‡๐—ฎ๐˜๐—ถ๐—ผ๐—ป
โ†’ ๐‘จ๐’“๐’•๐’†๐’“๐’Š๐’‚๐’ ๐’•๐’†๐’“๐’“๐’Š๐’•๐’๐’“๐’Š๐’†๐’” + ๐’„๐’๐’Š๐’๐’Š๐’„๐’‚๐’ ๐’๐’๐’„๐’‚๐’๐’Š๐’›๐’‚๐’•๐’Š๐’๐’

๐Ÿฉบ ๐—ฆ๐—จ๐—ฅ๐—š๐—˜๐—ฅ๐—ฌ

โ‘ฅ ๐—ฆ๐—ต๐—ผ๐—ฐ๐—ธ + ๐—™๐—น๐˜‚๐—ถ๐—ฑ & ๐—˜๐—น๐—ฒ๐—ฐ๐˜๐—ฟ๐—ผ๐—น๐˜†๐˜๐—ฒ ๐— ๐—ฎ๐—ป๐—ฎ๐—ด๐—ฒ๐—บ๐—ฒ๐—ป๐˜
โ†’ ๐‘ป๐’š๐’‘๐’†๐’” ๐’๐’‡ ๐’”๐’‰๐’๐’„๐’Œ + ๐’“๐’†๐’”๐’–๐’”๐’„๐’Š๐’•๐’‚๐’•๐’Š๐’๐’ + ๐’†๐’๐’†๐’„๐’•๐’“๐’๐’๐’š๐’•๐’† ๐’‚๐’ƒ๐’๐’๐’“๐’Ž๐’‚๐’๐’Š๐’•๐’Š๐’†๐’”

โ‘ฆ ๐—ง๐—ฟ๐—ฎ๐˜‚๐—บ๐—ฎ + ๐—”๐—ง๐—Ÿ๐—ฆ
โ†’ ๐‘ท๐’“๐’Š๐’Ž๐’‚๐’“๐’š ๐’”๐’–๐’“๐’—๐’†๐’š + ๐’•๐’“๐’‚๐’–๐’Ž๐’‚ ๐’‘๐’“๐’Š๐’๐’“๐’Š๐’•๐’Š๐’†๐’”

โ‘ง ๐—•๐˜‚๐—ฟ๐—ป๐˜€
โ†’ ๐‘ป๐‘ฉ๐‘บ๐‘จ + ๐’‡๐’๐’–๐’Š๐’… ๐’„๐’‚๐’๐’„๐’–๐’๐’‚๐’•๐’Š๐’๐’ + ๐’„๐’๐’Ž๐’‘๐’๐’Š๐’„๐’‚๐’•๐’Š๐’๐’๐’”

๐Ÿ‘ฉ๐Ÿปโ€โš•๏ธ ๐—ข๐—•๐—ฆ๐—ง๐—˜๐—ง๐—ฅ๐—œ๐—–๐—ฆ & ๐—š๐—ฌ๐—ก๐—”๐—˜๐—–๐—ข๐—Ÿ๐—ข๐—š๐—ฌ

โ‘จ ๐—ฃ๐—ผ๐˜€๐˜๐—ฝ๐—ฎ๐—ฟ๐˜๐˜‚๐—บ ๐—›๐—ฒ๐—บ๐—ผ๐—ฟ๐—ฟ๐—ต๐—ฎ๐—ด๐—ฒ
โ†’ ๐‘ช๐’‚๐’–๐’”๐’†๐’” + ๐Ÿฐ ๐‘ป๐’” + ๐’”๐’•๐’†๐’‘๐’˜๐’Š๐’”๐’† ๐’Ž๐’‚๐’๐’‚๐’ˆ๐’†๐’Ž๐’†๐’๐’•

โ‘ฉ ๐—”๐—ป๐˜๐—ฒ๐—ฝ๐—ฎ๐—ฟ๐˜๐˜‚๐—บ ๐—›๐—ฒ๐—บ๐—ผ๐—ฟ๐—ฟ๐—ต๐—ฎ๐—ด๐—ฒ
โ†’ ๐‘ท๐’๐’‚๐’„๐’†๐’๐’•๐’‚ ๐’‘๐’“๐’†๐’—๐’Š๐’‚ ๐’—๐’” ๐’‚๐’ƒ๐’“๐’–๐’‘๐’•๐’Š๐’ ๐’‘๐’๐’‚๐’„๐’†๐’๐’•๐’‚๐’†

โ‘ช ๐—›๐˜†๐—ฝ๐—ฒ๐—ฟ๐˜๐—ฒ๐—ป๐˜€๐—ถ๐˜ƒ๐—ฒ ๐——๐—ถ๐˜€๐—ผ๐—ฟ๐—ฑ๐—ฒ๐—ฟ๐˜€ ๐—ผ๐—ณ ๐—ฃ๐—ฟ๐—ฒ๐—ด๐—ป๐—ฎ๐—ป๐—ฐ๐˜†
โ†’ ๐‘ฎ๐’†๐’”๐’•๐’‚๐’•๐’Š๐’๐’๐’‚๐’ ๐‘ฏ๐‘ป๐‘ต + ๐’‘๐’“๐’†๐’†๐’„๐’๐’‚๐’Ž๐’‘๐’”๐’Š๐’‚ + ๐’†๐’„๐’๐’‚๐’Ž๐’‘๐’”๐’Š๐’‚

๐Ÿ”ฌ ๐—ฃ๐—”๐—ง๐—›๐—ข๐—Ÿ๐—ข๐—š๐—ฌ

โ‘ซ ๐—ก๐—ฒ๐—ผ๐—ฝ๐—น๐—ฎ๐˜€๐—ถ๐—ฎ & ๐—ง๐˜‚๐—บ๐—ผ๐—ฟ ๐— ๐—ฎ๐—ฟ๐—ธ๐—ฒ๐—ฟ๐˜€
โ†’ ๐‘ฏ๐’‚๐’๐’๐’Ž๐’‚๐’“๐’Œ๐’” + ๐’•๐’–๐’Ž๐’๐’“ ๐’Ž๐’‚๐’“๐’Œ๐’†๐’“๐’” + ๐’Š๐’Ž๐’‘๐’๐’“๐’•๐’‚๐’๐’• ๐’‚๐’”๐’”๐’๐’„๐’Š๐’‚๐’•๐’Š๐’๐’๐’”

โ‘ฌ ๐—–๐—ฒ๐—น๐—น ๐—œ๐—ป๐—ท๐˜‚๐—ฟ๐˜† & ๐—”๐—ฝ๐—ผ๐—ฝ๐˜๐—ผ๐˜€๐—ถ๐˜€
โ†’ ๐‘น๐’†๐’—๐’†๐’“๐’”๐’Š๐’ƒ๐’๐’† / ๐’Š๐’“๐’“๐’†๐’—๐’†๐’“๐’”๐’Š๐’ƒ๐’๐’† ๐’Š๐’๐’‹๐’–๐’“๐’š + ๐’‚๐’‘๐’๐’‘๐’•๐’๐’”๐’Š๐’” ๐’‘๐’‚๐’•๐’‰๐’˜๐’‚๐’š๐’”

๐Ÿ’Š ๐—ฃ๐—›๐—”๐—ฅ๐— ๐—”๐—–๐—ข๐—Ÿ๐—ข๐—š๐—ฌ

โ‘ญ ๐—”๐˜‚๐˜๐—ผ๐—ป๐—ผ๐—บ๐—ถ๐—ฐ ๐—ก๐—ฒ๐—ฟ๐˜ƒ๐—ผ๐˜‚๐˜€ ๐—ฆ๐˜†๐˜€๐˜๐—ฒ๐—บ ๐——๐—ฟ๐˜‚๐—ด๐˜€
โ†’ ๐‘บ๐’š๐’Ž๐’‘๐’‚๐’•๐’‰๐’๐’Ž๐’Š๐’Ž๐’†๐’•๐’Š๐’„๐’” + ๐’ƒ๐’๐’๐’„๐’Œ๐’†๐’“๐’” + ๐’‘๐’‚๐’“๐’‚๐’”๐’š๐’Ž๐’‘๐’‚๐’•๐’‰๐’†๐’•๐’Š๐’„ ๐’…๐’“๐’–๐’ˆ๐’”

โ‘ฎ ๐—”๐—ป๐˜๐—ถ๐—ต๐˜†๐—ฝ๐—ฒ๐—ฟ๐˜๐—ฒ๐—ป๐˜€๐—ถ๐˜ƒ๐—ฒ ๐——๐—ฟ๐˜‚๐—ด๐˜€
โ†’ ๐‘ซ๐’“๐’–๐’ˆ ๐’„๐’๐’‚๐’”๐’”๐’†๐’” + ๐’Ž๐’†๐’„๐’‰๐’‚๐’๐’Š๐’”๐’Ž๐’” + ๐’‚๐’…๐’—๐’†๐’“๐’”๐’† ๐’†๐’‡๐’‡๐’†๐’„๐’•๐’”

โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”

๐ŸŽฏ ๐—›๐—ข๐—ช ๐—ง๐—ข ๐—ฅ๐—˜๐—ฉ๐—œ๐—ฆ๐—˜ ๐—ง๐—›๐—˜๐—ฆ๐—˜ ๐Ÿญ๐Ÿฑ

โœ… ๐—ฆ๐—ต๐—ผ๐—ฟ๐˜ ๐—ก๐—ผ๐˜๐—ฒ๐˜€ โ†’ ๐Ÿฏ๐Ÿฌโ€“๐Ÿฐ๐Ÿฑ ๐—บ๐—ถ๐—ป/topic
โœ… ๐—ฃ๐—ฌ๐—ค๐˜€ โ†’ ๐—œ๐—บ๐—บ๐—ฒ๐—ฑ๐—ถ๐—ฎ๐˜๐—ฒ๐—น๐˜† ๐—ฎ๐—ณ๐˜๐—ฒ๐—ฟ ๐—ฟ๐—ฒ๐˜ƒ๐—ถ๐˜€๐—ถ๐—ผ๐—ป
โœ… ๐—”๐—ฐ๐˜๐—ถ๐˜ƒ๐—ฒ ๐—ฅ๐—ฒ๐—ฐ๐—ฎ๐—น๐—น โ†’ ๐—ช๐—ถ๐˜๐—ต๐—ผ๐˜‚๐˜ ๐—น๐—ผ๐—ผ๐—ธ๐—ถ๐—ป๐—ด ๐—ฎ๐˜ ๐—ป๐—ผ๐˜๐—ฒ๐˜€
โŒ ๐——๐—ผ๐—ปโ€™๐˜ ๐˜€๐˜๐—ฎ๐—ฟ๐˜ ๐—ป๐—ฒ๐˜„ ๐—น๐—ผ๐˜„-๐˜†๐—ถ๐—ฒ๐—น๐—ฑ ๐˜๐—ผ๐—ฝ๐—ถ๐—ฐ๐˜€
๐Ÿ”„ ๐—ฅ๐—ฒ๐˜ƒ๐—ถ๐˜€๐—ถ๐˜ ๐—บ๐—ถ๐˜€๐˜๐—ฎ๐—ธ๐—ฒ๐˜€ ๐—ฏ๐—ฒ๐—ณ๐—ผ๐—ฟ๐—ฒ ๐˜€๐—น๐—ฒ๐—ฒ๐—ฝ๐—ถ๐—ป๐—ด

๐Ÿ”ฅ ๐Ÿญ๐Ÿฑ ๐—ง๐—ข๐—ฃ๐—œ๐—–๐—ฆ. ๐—ข๐—ก๐—˜ ๐—ฆ๐—˜๐—ง.
โญ ๐— ๐—”๐—ซ๐—œ๐— ๐—จ๐—  ๐—ฅ๐—˜๐—ฉ๐—œ๐—ฆ๐—œ๐—ข๐—ก ๐—ฉ๐—”๐—Ÿ๐—จ๐—˜.

๐Ÿ“Œ ๐—ฆ๐—”๐—ฉ๐—˜ ๐—ง๐—›๐—œ๐—ฆ ๐—ฃ๐—ข๐—ฆ๐—ง

๐Ÿ’ฅ ๐—–๐—˜๐—ฅ๐—˜๐—•๐—˜๐—Ÿ๐—Ÿ๐—จ๐—  ๐——๐—œ๐—ฆ๐—–๐—ข๐—จ๐—ก๐—ง ๐—–๐—ข๐——๐—˜ โ€” ๐— ๐—”๐—š๐—œ๐—–๐—•๐—ง๐—ฅ (10% OFF)๐Ÿ’ฅ
โค4
๐Ÿฉบ STOMACH PATHOLOGY โ€” ONE-LINERS

NEET PG โ€ข FMGE โ€ข INI-CET RAPID REVISION

Stomach Lesions โ€ข Exam Buzzwords

H. pylori gastritis = Curved bacilli, urease positive, chronic active gastritis
Autoimmune (Type A) gastritis = Parietal cell antibodies, intrinsic factor deficiency, B12 deficiency
Menetrier disease = Giant rugal folds, protein-losing gastropathy, โ†‘ TGF-ฮฑ
Zollingerโ€“Ellison syndrome = Gastrinoma (duodenum/pancreas), โ†‘ gastrin, multiple ulcers
Gastric ulcer = NSAIDs, H. pylori, stress; clean-based, incisura angularis common
Duodenal ulcer = Gastrin excess (ZES), H. pylori; anterior wall, near pylorus
Stress (acute) ulcers = Curling (burns), Cushing (head injury), multiple superficial ulcers
Hypertrophic pyloric stenosis = Infants, projectile vomiting, โ†“ pyloric canal, olive mass
Peptic stricture = Healing of chronic ulcers โ†’ fibrosis and luminal narrowing
MALT lymphoma = H. pylori associated, low-grade B-cell lymphoma
Diffuse large B-cell lymphoma = Most common aggressive gastric lymphoma
Lauren classification = Intestinal type (gland-forming) > Diffuse type (signet ring cells)
Intestinal type adenocarcinoma = Atrophic gastritis โ†’ intestinal metaplasia โ†’ dysplasia
Diffuse type adenocarcinoma = E-cadherin (CDH1) loss, linitis plastica
Signet ring cell carcinoma = Mucin pushing nucleus to periphery, diffuse type
Hereditary diffuse gastric cancer = CDH1 mutation, lobular breast cancer association
Familial adenomatous polyposis = Fundic gland polyps, duodenal adenomas
Gastric polyps โ€“ Fundic gland = Associated with FAP, usually multiple
Gastric polyps โ€“ Hyperplastic = Chronic gastritis, H. pylori, bleeding common
Gastric polyps โ€“ Adenomatous = Premalignant, intestinal type metaplasia
Menetrier vs Mรฉnรฉtrier mimic (ZES) = Menetrier (โ†“ acid), ZES (โ†‘ acid)
CMV gastritis = Large cells with โ€œowlโ€™s eyeโ€ intranuclear inclusions
Portal hypertensive gastropathy = Mosaic snake-skin pattern in mucosa
Erosive gastritis = NSAIDs, alcohol, bile reflux; superficial erosions
Atrophic gastritis = Loss of glands, intestinal metaplasia, โ†‘ risk of carcinoma
Intestinal metaplasia = Goblet cells in gastric mucosa, precancerous lesion
Dysplasia in stomach = Low-grade โ†’ architectural distortion; High-grade โ†’ carcinoma in situ
Carcinoid tumor = ECL cell hyperplasia, MEN1 association
GIST (stomach) = c-KIT (CD117) positive, most common mesenchymal tumor
Pernicious anemia = IF deficiency โ†’ B12 deficiency โ†’ macrocytic anemia

Clinical Pearls

Gastric ulcer โ†’ Pain after food
Duodenal ulcer โ†’ Pain relieved by food / antacids
Atrophic gastritis โ†’ High risk of adenocarcinoma
Menetrier โ†’ Protein loss (edema, hypoalbuminemia)
Pernicious anemia โ†’ B12 deficiency

Mnemonic โ€” Gastric Polyps

F โ€“ H โ€“ A

F = Fundic gland โ†’ FAP
H = Hyperplastic โ†’ H. pylori
A = Adenomatous โ†’ Premalignant

High-Yield Summary

H. pylori โ†’ Gastritis, Ulcer, MALT lymphoma, Adenocarcinoma
ZES โ†’ โ†‘ Gastrin โ†’ Multiple ulcers
CDH1 mutation โ†’ Diffuse type adenocarcinoma
Intestinal metaplasia โ†’ Precancerous
Pernicious anemia โ†’ IF deficiency โ†’ B12 deficiency
@marrowdailycore
@marrowdailycore
โค10๐Ÿ‘3
๐Ÿ”ฅ PATHOLOGY โ€” THE LAST-MINUTE MUST KNOWS ๐Ÿงฌ

NEET PG mein Pathology ke ye high-yield spotters + one-liners miss mat karna ๐Ÿ‘€

โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”

๐Ÿ”ฌ HISTOPATHOLOGY SPOTTERS

๐Ÿฉธ IRON DEFICIENCY ANAEMIA
โ†“ Iron โ€ข โ†‘ TIBC โ€ข โ†“ Ferritin โญ

๐Ÿฉธ ANAEMIA OF CHRONIC DISEASE
โ†“ TIBC โ€ข โ†‘ Ferritin

๐Ÿงฌ ABETALIPOPROTEINAEMIA
Acanthocytes + Retinitis pigmentosa + Neurological signs

๐Ÿ”ฌ APML
Auer rods + DIC
t(15;17) โ†’ PML-RARA โญ

๐ŸŒŒ BURKITT LYMPHOMA
Starry-sky appearance + Jaw/abdominal mass

๐Ÿฆ‰ HODGKIN LYMPHOMA
Reed-Sternberg โ†’ Owl-eye cells
Treatment โ†’ ABVD

๐Ÿฉธ G6PD DEFICIENCY
Bite cells + Heinz bodies

๐Ÿฉธ HEREDITARY SPHEROCYTOSIS
Spherocytes + โ†‘ MCHC

โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”

๐Ÿ“š DIRECT HISTOLOGY HITS

๐Ÿฆ‹ Papillary Thyroid Carcinoma
Orphan Annie-eye nuclei + Psammoma bodies

๐Ÿซ˜ Chromophobe RCC
Plant-like cell membrane + Perinuclear halo

๐Ÿฆด Ewing Sarcoma
Small round blue cells + EWSR1-FLI1

๐ŸŽ€ Phyllodes Tumour
Leaf-like architecture

โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”

โšก RAPID-FIRE RECALL

Auer rods โ†’ APML
Starry sky โ†’ Burkitt
Owl-eye cells โ†’ Hodgkin
Bite cells + Heinz bodies โ†’ G6PD
Spherocytes + โ†‘ MCHC โ†’ Hereditary spherocytosis
Orphan Annie nuclei โ†’ Papillary thyroid carcinoma
Leaf-like pattern โ†’ Phyllodes tumour

โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”

๐ŸŽฏ SAVE THIS. REVISE THIS. SCORE FROM THIS.

๐Ÿ“Œ Cerebellum BTR Code: MAGICBTR (10 % ) OFF
โค7๐Ÿ‘1
This media is not supported in your browser
VIEW IN TELEGRAM
๐Ÿ˜1
โ•ญโ”โ”โ” ๐Ÿฉบ PSM UPDATES 2026 โ”โ”โ”โ•ฎ
PART 1 โ€ข NEET PG ๐Ÿญ
โ•ฐโ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ•ฏ

๐Ÿฉธ ANEMIA MUKT BHARAT

7 ร— 7 ร— 7 ๐Ÿ”ฅ

7 BENEFICIARIES
โ€ข 6โ€“59 months
โ€ข 5โ€“9 years
โ€ข Adolescents 10โ€“19 yr
โ€ข WRA 20โ€“49 yr
โ€ข Pregnant women
โ€ข Lactating women
โ€ข LBW infants 0โ€“6 months

7 INTERVENTIONS
๐Ÿ’Š IFA prophylaxis
๐Ÿชฑ Biannual deworming
๐Ÿ“ข T4 โ†’ Test โ€ข Treat โ€ข Talk โ€ข Track
๐Ÿฉธ Digital/POC testing
๐Ÿฝ๏ธ IFA-fortified foods
๐Ÿ”Ž Non-nutritional causes
๐Ÿฅ— โ€œEating Rightโ€ approach

7 INSTITUTIONAL MECHANISMS
๐Ÿ›๏ธ Inter-ministerial coordination
๐Ÿ“ฆ IFA + deworming supply chain
๐Ÿซ School/Anganwadi testing
๐Ÿ˜๏ธ VHSND convergence
๐Ÿค Jan Chetna
๐Ÿ“ฑ Digital tracking
โ†’ JANANI + RBSK + U-WIN

๐Ÿ‘ถ SAMAGRA SHISHU BAL SWASTHYA

๐ŸŽฏ Theme: Complete care in first 3 years

HBNC + HBYC โ†’ ONE PLATFORM

โš ๏ธ Risk groups โ†’ LBW โ€ข SAM โ€ข Prematurity

๐Ÿ‘ถ At-risk newborn
โ†’ 9 visits / first 42 days

๐Ÿง’ At-risk toddler
โ†’ 8 extra visits till 36 months

๐Ÿ‘ฉโ€โš•๏ธ ASHA + CHO + ANM + AWW

๐Ÿ“ฑ Child Apps
JANANI โ†’ Maternal/delivery
U-WIN โ†’ Immunisation
POSHAN Tracker โ†’ Nutrition
RBSK 2.0 โ†’ Screening/referral

๐Ÿ“ฑ JANANI APP

Journey of Antenatal, Natal & Neonatal Integrated Care

๐Ÿคฐ ANC โ†’ Delivery โ†’ PNC โ†’ Newborn

๐Ÿท๏ธ โ€œSehat ke Sath, Every Step of Careโ€

๐Ÿ”— U-WIN + POSHAN Tracker

๐Ÿคฐ SUMAN ROADMAP 2030

๐Ÿ“… 29 June 2026
๐Ÿ›๏ธ MoHFW
๐Ÿงฉ RMNCAH + N

๐ŸŽฏ MMR <70/100,000 LB by 2030

๐Ÿ”ฅ Remember:
โ€ข Life-cycle approach
โ€ข 4-stage high-risk pregnancy care
โ€ข 130 districts / 13 high-focus states
โ€ข Jan Bhagidari
โ€ข SDG 2030

๐Ÿง’ RBSK 2.0

๐Ÿ“… 3 May 2026

๐Ÿ”ฅ 38 health conditions

THE CLASSIC 4Ds

Defects at birth
Diseases
Deficiencies
Developmental delays

๐Ÿ“ฑ Digital health cards
โšก Real-time tracking
๐Ÿ‘ถ Birth โ†’ 18 years

๐Ÿชช ABHA

Ayushman Bharat Health Account

โ†’ Unique digital health ID
โ†’ Store โ€ข Access โ€ข Share health records

๐Ÿค– KHUSHI AI

โ€œKhushi โ€” Aapki E-Sanginiโ€

๐Ÿ“ TB Mukt Bharat App
๐Ÿ“… 24 March 2026

๐ŸŒ 12 Indian languages
๐ŸŽ™๏ธ Voice interaction
๐Ÿ’Š Pill reminders
๐Ÿ“ Clinic finder
๐Ÿค Health-worker connection

๐Ÿซ TB MUKT BHARAT APP

๐Ÿ”ฅ Khushi AI
โฐ Treatment reminders
๐Ÿ“ GPS facility finder
๐Ÿฅ— Ni-kshay Mitra tracking
๐Ÿ“Š Provider dashboard
๐Ÿ’Š Treatment adherence

๐Ÿ’Š BPaLM REGIMEN

๐Ÿ”ฅ MDR/RR-TB

Bedaquiline
Pretomanid
Linezolid
Moxifloxacin

โฑ๏ธ 6 MONTHS

๐Ÿ‘ค >14 years
๐Ÿšซ CNS / osteoarticular / miliary TB excluded

โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”
๐Ÿญ SAVE โ€ข SHARE โ€ข REVISE
PSM UPDATES 2026 | PART 1/3
โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”
https://whatsapp.com/channel/0029VanTshI0LKZAZreeWS46
โค6
Marrow Daily Core
โ•ญโ”โ”โ” ๐Ÿฉบ PSM UPDATES 2026 โ”โ”โ”โ•ฎ PART 1 โ€ข NEET PG ๐Ÿญ โ•ฐโ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ•ฏ ๐Ÿฉธ ANEMIA MUKT BHARAT 7 ร— 7 ร— 7 ๐Ÿ”ฅ 7 BENEFICIARIES โ€ข 6โ€“59 months โ€ข 5โ€“9 years โ€ข Adolescents 10โ€“19 yr โ€ข WRA 20โ€“49 yr โ€ข Pregnant women โ€ข Lactating women โ€ข LBW infants 0โ€“6 months 7 INTERVENTIONSโ€ฆ
โ•ญโ”โ”โ” ๐Ÿฉบ PSM UPDATES 2026 โ”โ”โ”โ•ฎ
PART 2 โ€ข NEET PG ๐Ÿญ
โ•ฐโ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ•ฏ

๐ŸŒ WHO DRUG-SENSITIVE TB

๐Ÿ”ฅ New regimen:

2HPZM / 2HPM

H โ†’ Isoniazid
P โ†’ Rifapentine
Z โ†’ Pyrazinamide
M โ†’ Moxifloxacin

โš ๏ธ NOT ADOPTED IN INDIA

๐Ÿ’‰ ADULT TB VACCINATION

๐Ÿ“Œ Trial basis

WHO GETS IT?
โ‰ฅ60 years
BMI <18 kg/mยฒ
TB in last 5 years
Close contacts
Diabetes
Tobacco users

๐Ÿšซ C/I โ†’ Immunosuppressed

๐Ÿ“ฑ Tracking โ†’ TB-WIN

๐Ÿฆ  LEPROSY MUKT BHARAT 2023โ€“27

๐ŸŽฏ Eradication โ†’ 2027

๐Ÿ”ฅ ABSULS
Active ASHA-Based Surveillance
for Leprosy Suspects

๐Ÿ“ฑ Nikusth 2.0
โ†’ Case + treatment + rehabilitation tracking

๐Ÿ’Š Contact PEP
โ†’ Single-dose Rifampicin

๐Ÿ’ฐ Disability rehabilitation surgery incentive
โ†’ Up to โ‚น12,000

๐ŸŽฏ NLEP TARGETS

๐Ÿ“‰ Prevalence โ†’ <1/10,000
๐Ÿ“‰ New case detection โ†’ <10/100,000
๐Ÿ“‰ Grade-2 disability โ†’ <1/10 lakh
๐Ÿ“ˆ Cure rate โ†’ >90%

๐Ÿ”ฅ Leprosy Mukt Bharat โ†’ 2027

๐ŸฆŸ KALA-AZAR

๐ŸŽฏ Elimination target โ†’ 2027

โœ… Elimination target achieved

๐Ÿงฌ NACP PHASE-V

๐Ÿ”ฅ 5 CORE GOALS

โ†“ New HIV infections 80%
โ†“ AIDS mortality 80%
๐Ÿšซ Eliminate vertical HIV + syphilis
๐Ÿฅ Universal STI/RTI services
โŒ Eliminate stigma & discrimination

๐ŸŽ—๏ธ MISSION AIDS SURAKSHA

๐ŸŽฏ HIV control โ†’ 1 December 2027

๐Ÿ”ฅ 95 โ€“ 95 โ€“ 99

95% โ†’ Know HIV status
95% โ†’ Diagnosed โ†’ ART
99% โ†’ On treatment โ†’ Viral suppression

๐Ÿ“Œ Viral suppression
โ†’ HIV RNA โ‰ค200 copies/mL

๐Ÿฅ SURAKSHA SANKALP KARYASHALA

๐Ÿ“ 219 high-priority districts

๐ŸŸข SURAKSHIT PLUS
โ†’ 95-95-99 achieved
โ†’ 0 MTCT HIV + Syphilis + Hep B
โ†’ HIV/Syphilis dual testing in 1st trimester

๐ŸŸข SURAKSHIT
โ†’ All 95-95-99 achieved

๐ŸŸก SAKSHAM
โ†’ 2/3 achieved

๐Ÿ”ด SANGHARSHSHEEL
โ†’ โ‰ฅ1/3 achieved

๐Ÿงซ SCORTCH

S โ†’ Syphilis
C โ†’ CMV
O โ†’ Other โ†’ Zika โ€ข Malaria โ€ข HIV
R โ†’ Rubella
T โ†’ Toxoplasmosis
C โ†’ Chickenpox / Varicella
H โ†’ HSV

๐Ÿ”ฅ SCORTCH = UPDATED TORCH

โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”
๐Ÿญ SAVE โ€ข SHARE โ€ข REVISE
PSM UPDATES 2026 | PART 2/3
โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”
https://whatsapp.com/channel/0029VanTshI0LKZAZreeWS46
โค6
Marrow Daily Core
โ•ญโ”โ”โ” ๐Ÿฉบ PSM UPDATES 2026 โ”โ”โ”โ•ฎ PART 2 โ€ข NEET PG ๐Ÿญ โ•ฐโ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ•ฏ ๐ŸŒ WHO DRUG-SENSITIVE TB ๐Ÿ”ฅ New regimen: 2HPZM / 2HPM H โ†’ Isoniazid P โ†’ Rifapentine Z โ†’ Pyrazinamide M โ†’ Moxifloxacin โš ๏ธ NOT ADOPTED IN INDIA ๐Ÿ’‰ ADULT TB VACCINATION ๐Ÿ“Œ Trial basis โ€ฆ
โ•ญโ”โ”โ” ๐Ÿฉบ PSM UPDATES 2026 โ”โ”โ”โ•ฎ PART 3 โ€ข NEET PG ๐Ÿญ โ•ฐโ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ•ฏ
๐Ÿ’‰ SAYANA PRESS
๐Ÿ”ฅ Self-injectable contraceptive
DMPA โ†’ 104 mg / 0.65 mL SC
๐Ÿ†š ANTARA 150 mg โ†’ IM โ†’ Provider
๐Ÿ†š SAYANA PRESS 104 mg โ†’ SC โ†’ Self/Provider ๐Ÿ“ Thigh / Abdomen โฑ๏ธ Every 3 months
๐ŸŽ—๏ธ CERVICAL CANCER SCREENING
๐Ÿ”ฅ Self-collected hr-HPV
โŒ Negative โ†’ ๐Ÿ” Repeat after 3 years
๐ŸŒ WHO ELIMINATION TARGET
90 โ€“ 70 โ€“ 90
๐Ÿ’‰ 90% vaccinated ๐Ÿ”ฌ 70% screened ๐Ÿ’Š 90% diagnosed โ†’ treated
๐Ÿ’‰ NATIONAL HPV VACCINATION CAMPAIGN 2026
๐Ÿ“… 28 Feb 2026 ๐Ÿ“ Ajmer, Rajasthan
๐Ÿ‘ง Target: 14-year-old girls
girls turning 15 within 90 days
๐Ÿ’‰ Gardasil-4 โ†’ HPV 6, 11, 16, 18
๐Ÿ’Š Single dose 0.5 mL IM ๐Ÿ“ Left upper arm
๐Ÿฅ Government health facilities โœ๏ธ Parental consent mandatory ๐Ÿ“ฑ U-WIN registration
๐ŸŽฏ 90-day campaign โ†’ UIP inclusion
๐Ÿฅ— SAKSHAM ANGANWADI & POSHAN 2.0
๐ŸŽฏ Pregnant + lactating women ๐ŸŽฏ Adolescent girls ๐ŸŽฏ Children 0โ€“6 years
๐Ÿ”ฅ Annual targets:
โ†“ Stunting/malnutrition โ†’ 2% โ†“ Anaemia โ†’ 3%
๐Ÿ”— Merged: POSHAN Abhiyaan + ICDS + Scheme for Adolescent Girls
๐Ÿ“ฑ POSHAN Tracker ๐ŸŒฑ Poshan Vatika ๐Ÿ“š Poshan Bhi Padhai Bhi ๐Ÿ‡ฎ๐Ÿ‡ณ Poshan Maah โ†’ September
๐ŸฆŸ QDENGA โ€” DENGUE VACCINE
๐Ÿ’‰ TAK-003
๐Ÿงฌ Live attenuated ๐ŸŽฏ DEN 1, 2, 3, 4
๐Ÿ’Š 2 ร— 0.5 mL SC โฑ๏ธ 3 months apart ๐Ÿ‘ค 4โ€“60 years
โญ Key clue: NO PRE-SCREENING REQUIRED
๐Ÿ“Š DIGITAL CENSUS 2027
๐Ÿ‡ฎ๐Ÿ‡ณ FIRST COMPLETELY DIGITAL CENSUS
๐Ÿ›๏ธ Ministry โ†’ Home Affairs
PHASE 1 ๐Ÿ  Houselisting + Housing
PHASE 2 ๐Ÿ‘ฅ Population Enumeration
๐Ÿ’ป 4 Digital Tools: โ†’ House Listing Block Creator โ†’ HLO Mobile App โ†’ Self Enumeration Portal โ†’ Census Management & Monitoring System
๐Ÿ“ˆ DEMOGRAPHIC UPDATES
CBR โ†’ 18.3 โ†‘ Bihar | โ†“ A&N
CDR โ†’ 6.4 โ†‘ Chhattisgarh | โ†“ Chandigarh
IMR โ†’ 24/1000 โ†‘ MP | โ†“ Manipur
MMR โ†’ 87/100,000 โ†‘ UP | โ†“ Kerala
Lifetime maternal risk โ†’ 0.18%
U5MR โ†’ 29/1000 โ†‘ MP | โ†“ Kerala
NMR โ†’ 19/1000 โ†‘ MP | โ†“ Kerala
Natural growth โ†’ 1.19 โ†‘ Bihar | โ†“ A&N
Sex ratio at birth โ†’ 917 โ†‘ Chhattisgarh | โ†“ Uttarakhand
๐Ÿ“Š NFHS-6 | 2023โ€“24
๐Ÿ‘ถ Stunting โ†’ 29.3% ๐Ÿ‘ถ Severe wasting โ†’ 5.2% ๐Ÿ’‰ Full immunisation โ†’ 87.1% ๐Ÿฆ  Rotavirus โ†’ 36.4% โ†’ 85.4%
โค๏ธ TFR โ†’ 2.0 ๐Ÿ’Š CPR โ†’ 69.1% ๐Ÿคฐ ANC registration โ†’ 95.9% ๐Ÿคฐ 1st trimester ANC โ†’ 76.2% ๐Ÿฅ Institutional delivery โ†’ 90.6%
๐Ÿ’Š IFA โ‰ฅ100 days โ†’ 54.9% ๐Ÿ’Š IFA โ‰ฅ180 days โ†’ 37.8%
๐ŸฆŸ IXCHIQ โ€” CHIKUNGUNYA VACCINE
๐Ÿฅ‡ First chikungunya vaccine
๐Ÿ’‰ Live attenuated ๐Ÿ’‰ 0.5 mL IM ๐Ÿ‘ค >18 years
โญ Single dose โ†’ ~99% protective antibody response within 28 days
๐ŸŒ 2026 HEALTH DAY THEMES
๐Ÿฆ  Leprosy โ†’ Leprosy is curable, real challenge is stigma
๐ŸŽ—๏ธ Cancer โ†’ United by Unique
โš–๏ธ Obesity โ†’ 8 billion reasons to act on obesity
๐Ÿซ TB โ†’ Yes we can end TB: led by countries, powered by people
โค๏ธ Health โ†’ Together for health. Stand with science.
๐ŸฆŸ Malaria โ†’ Driven to end Malaria, now we can, now we must
๐Ÿง  Mental Health โ†’ It is time to prioritise Mental Health in the Workplace
๐ŸŽ—๏ธ AIDS โ†’ Rethink, Rebuild, Rise
โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ” ๐Ÿ”ฅ PSM UPDATES 2026 โ€” COMPLETE ๐Ÿญ SAVE IT FOR LAST-MINUTE REVISION โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”โ”https://whatsapp.com/channel/0029VanTshI0LKZAZreeWS46
โค7
Updates in medicine 2026
๐Ÿ˜5โค3
PSM UPDATES 2026
โค6๐Ÿ’ฏ2
Most probably 2nd september the official Notification will be published as per our resources.
Possible Exam - NOVEMBER 2026 (1st week)
๐Ÿ‘2
Those who are going to give NEETPG 2026 must go through this Message

https://whatsapp.com/channel/0029VbCcF2iFCCoTeLTQts0h/365
โค1